Skip to main content
Erschienen in: Indian Journal of Gastroenterology 3/2019

10.06.2019 | Original Article

Interpretation and implementation of the revised European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) guidelines on pediatric celiac disease amongst consultant general pediatricians in Southwest of England

verfasst von: Siba Prosad Paul, Helen Louise Adams, Dharamveer Basude, Collaborators

Erschienen in: Indian Journal of Gastroenterology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Celiac disease (CD) is a lifelong condition with significant morbidity and requires an accurate diagnosis. Guidelines for pediatric CD were revised by the European and British Societies of Paediatric Gastroenterology Hepatology and Nutrition in 2012 and 2013, respectively. New recommendations introduced non-biopsy pathway (NBP) of diagnosis for a selective group of symptomatic children whose anti-tissue transglutaminase (anti-tTG) antibody titer is greater than ten times upper limit of normal. A clear understanding of the guidelines amongst consultant pediatricians will ensure all children with suspected CD receive a prompt and secure diagnosis. The aim of this study was to establish the interpretation and implementation of the revised guideline for CD amongst consultant general pediatricians in Southwest England (SWE) during the study period.

Methods

Telephone/email survey was conducted amongst consultant general pediatricians (n ≈ 140) working in 12 secondary care hospitals across SWE. The survey included eight questions incorporating three main themes: understanding of diagnostic pathway particularly for non-biopsy diagnosis, awareness of laboratory tests involved, and variations in practice in relation to the revised guidelines.

Results

Responses were available from 101/140 (72%). One hundred respondents were aware of the revised guidelines for diagnosing CD. However, only 17 respondents stated all the criteria of the guideline required for diagnosis by NBP, with further 17 seeking immediate advice from a specialist. Forty-four listed both the criteria for HLA-DQ2/DQ8 testing applicable to pediatricians. Forty-nine out of 100 pediatricians would commence gluten-free diet only after all the results were available. Thirty-three pediatricians also considered asymptomatic children with high anti-tTG titer eligible for diagnosis of CD by NBP.

Conclusions

There is a need for improved understanding of revised CD guidelines amongst consultant general pediatricians especially while using the NBP and requesting HLA-DQ2/DQ8 testing.
Literatur
1.
Zurück zum Zitat Husby S, Koletzko S, Korponay-Szabó IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54:136–60. Husby S, Koletzko S, Korponay-Szabó IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54:136–60.
2.
Zurück zum Zitat Bingley PJ, Williams AJ, Norcross AJ, et al. Undiagnosed coeliac disease at age seven: population based prospective birth cohort study. BMJ. 2004;328:322–3. Bingley PJ, Williams AJ, Norcross AJ, et al. Undiagnosed coeliac disease at age seven: population based prospective birth cohort study. BMJ. 2004;328:322–3.
3.
Zurück zum Zitat Mustalahti K, Catassi C, Reunanen A, et al. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med. 2010;42:587–95. Mustalahti K, Catassi C, Reunanen A, et al. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med. 2010;42:587–95.
4.
Zurück zum Zitat Paul SP, Hoghton M, Sandhu B. Limited role of HLA DQ2/8 genotyping in diagnosing coeliac disease. Scott Med J. 2017;62:25–7.CrossRefPubMed Paul SP, Hoghton M, Sandhu B. Limited role of HLA DQ2/8 genotyping in diagnosing coeliac disease. Scott Med J. 2017;62:25–7.CrossRefPubMed
5.
Zurück zum Zitat Paul SP, Harries SL, Basude D. Barriers to implementing the revised ESPGHAN guidelines for coeliac disease in children: a cross sectional survey of coeliac screen reporting in laboratories in England. Arch Dis Child. 2017;102:942–6.CrossRefPubMed Paul SP, Harries SL, Basude D. Barriers to implementing the revised ESPGHAN guidelines for coeliac disease in children: a cross sectional survey of coeliac screen reporting in laboratories in England. Arch Dis Child. 2017;102:942–6.CrossRefPubMed
6.
Zurück zum Zitat Murch S, Jenkins H, Auth M, et al. Joint BSPGHAN and Coeliac UK guidelines for the diagnosis and management of coeliac disease in children. Arch Dis Child. 2013;98:806–11. Murch S, Jenkins H, Auth M, et al. Joint BSPGHAN and Coeliac UK guidelines for the diagnosis and management of coeliac disease in children. Arch Dis Child. 2013;98:806–11.
7.
Zurück zum Zitat Trovato CM, Montuori M, Anania C, et al. Are ESPGHAN “biopsy-sparing” guidelines for celiac disease also suitable for asymptomatic patients? Am J Gastroenterol. 2015;110:1485–9. Trovato CM, Montuori M, Anania C, et al. Are ESPGHAN “biopsy-sparing” guidelines for celiac disease also suitable for asymptomatic patients? Am J Gastroenterol. 2015;110:1485–9.
8.
Zurück zum Zitat Paul SP, Sandhu BK, Spray CH, Basude D, Ramani P. Evidence supporting serology based pathway for diagnosing coeliac disease in asymptomatic children from high-risk groups. J Pediatr Gastroenterol Nutr. 2018;66:641–4.CrossRefPubMed Paul SP, Sandhu BK, Spray CH, Basude D, Ramani P. Evidence supporting serology based pathway for diagnosing coeliac disease in asymptomatic children from high-risk groups. J Pediatr Gastroenterol Nutr. 2018;66:641–4.CrossRefPubMed
9.
Zurück zum Zitat Paul SP, Mazhar H, Spray CH. Applicability of the new ESPGHAN guidelines for diagnosing coeliac disease in children from resource limited countries. J Coll Physicians Surg Pak. 2015;25:455–7.PubMed Paul SP, Mazhar H, Spray CH. Applicability of the new ESPGHAN guidelines for diagnosing coeliac disease in children from resource limited countries. J Coll Physicians Surg Pak. 2015;25:455–7.PubMed
10.
Zurück zum Zitat Al-Musawi ZM. Is high tissue transglutaminase antibody titers enough to diagnose coeliac disease in children? Karbala J Med. 2010;3:860–6. Al-Musawi ZM. Is high tissue transglutaminase antibody titers enough to diagnose coeliac disease in children? Karbala J Med. 2010;3:860–6.
11.
Zurück zum Zitat Bhattacharya M, Lomash A, Sakhuja P, Dubey AP, Kapoor S. Clinical and histopathological correlation of duodenal biopsy with IgA anti-tissue transglutaminase titers in children with coeliac disease. Indian J Gastroenterol. 2014;33:350–4.CrossRefPubMed Bhattacharya M, Lomash A, Sakhuja P, Dubey AP, Kapoor S. Clinical and histopathological correlation of duodenal biopsy with IgA anti-tissue transglutaminase titers in children with coeliac disease. Indian J Gastroenterol. 2014;33:350–4.CrossRefPubMed
12.
Zurück zum Zitat Paul SP, Kirkham EN. Celiac disease - a case series from North India: correspondence. Indian J Pediatr. 2016;83:760–1.CrossRefPubMed Paul SP, Kirkham EN. Celiac disease - a case series from North India: correspondence. Indian J Pediatr. 2016;83:760–1.CrossRefPubMed
Metadaten
Titel
Interpretation and implementation of the revised European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) guidelines on pediatric celiac disease amongst consultant general pediatricians in Southwest of England
verfasst von
Siba Prosad Paul
Helen Louise Adams
Dharamveer Basude
Collaborators
Publikationsdatum
10.06.2019
Verlag
Springer India
Erschienen in
Indian Journal of Gastroenterology / Ausgabe 3/2019
Print ISSN: 0254-8860
Elektronische ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-019-00952-9

Weitere Artikel der Ausgabe 3/2019

Indian Journal of Gastroenterology 3/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.